These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24662035)

  • 21. Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery.
    Ruggeri BA; Camp F; Miknyoczki S
    Biochem Pharmacol; 2014 Jan; 87(1):150-61. PubMed ID: 23817077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genomics and transcriptomics in drug discovery.
    Dopazo J
    Drug Discov Today; 2014 Feb; 19(2):126-32. PubMed ID: 23773860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alzheimer's disease drug development: translational neuroscience strategies.
    Cummings JL; Banks SJ; Gary RK; Kinney JW; Lombardo JM; Walsh RR; Zhong K
    CNS Spectr; 2013 Jun; 18(3):128-38. PubMed ID: 23472637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Network-based discovery through mechanistic systems biology. Implications for applications--SMEs and drug discovery: where the action is.
    Benson N
    Drug Discov Today Technol; 2015 Aug; 15():41-8. PubMed ID: 26464089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The treatment of Alzheimer's disease using Chinese medicinal plants: from disease models to potential clinical applications.
    Su Y; Wang Q; Wang C; Chan K; Sun Y; Kuang H
    J Ethnopharmacol; 2014 Mar; 152(3):403-23. PubMed ID: 24412377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A systems approach to drug discovery in Alzheimer's disease.
    Shelanski M; Shin W; Aubry S; Sims P; Alvarez MJ; Califano A
    Neurotherapeutics; 2015 Jan; 12(1):126-31. PubMed ID: 25608936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer's disease.
    Li C; Ebrahimi A; Schluesener H
    Ageing Res Rev; 2013 Jan; 12(1):116-40. PubMed ID: 22982398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alzheimer's disease: from pathology to therapeutic approaches.
    Jakob-Roetne R; Jacobsen H
    Angew Chem Int Ed Engl; 2009; 48(17):3030-59. PubMed ID: 19330877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel disease-modifying therapeutics for the treatment of Alzheimer's disease.
    Léger GC; Massoud F
    Expert Rev Clin Pharmacol; 2013 Jul; 6(4):423-42. PubMed ID: 23927670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systems biology and theranostic approach to drug discovery and development to treat traumatic brain injury.
    Zhang Z; Larner SF; Kobeissy F; Hayes RL; Wang KK
    Methods Mol Biol; 2010; 662():317-29. PubMed ID: 20824479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integration not isolation: arguing the case for quantitative and systems pharmacology in drug discovery and development.
    Agoram BM; Demin O
    Drug Discov Today; 2011 Dec; 16(23-24):1031-6. PubMed ID: 22020181
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unveiling the role of network and systems biology in drug discovery.
    Pujol A; Mosca R; Farrés J; Aloy P
    Trends Pharmacol Sci; 2010 Mar; 31(3):115-23. PubMed ID: 20117850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.
    Kreft AF; Martone R; Porte A
    J Med Chem; 2009 Oct; 52(20):6169-88. PubMed ID: 19694467
    [No Abstract]   [Full Text] [Related]  

  • 34. Magnetic resonance imaging of Alzheimer's pathology in the brains of living transgenic mice: a new tool in Alzheimer's disease research.
    Jack CR; Marjanska M; Wengenack TM; Reyes DA; Curran GL; Lin J; Preboske GM; Poduslo JF; Garwood M
    Neuroscientist; 2007 Feb; 13(1):38-48. PubMed ID: 17229974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Towards a 21st-century roadmap for biomedical research and drug discovery: consensus report and recommendations.
    Langley GR; Adcock IM; Busquet F; Crofton KM; Csernok E; Giese C; Heinonen T; Herrmann K; Hofmann-Apitius M; Landesmann B; Marshall LJ; McIvor E; Muotri AR; Noor F; Schutte K; Seidle T; van de Stolpe A; Van Esch H; Willett C; Woszczek G
    Drug Discov Today; 2017 Feb; 22(2):327-339. PubMed ID: 27989722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibitors of BACE for treating Alzheimer's disease: a fragment-based drug discovery story.
    Stamford A; Strickland C
    Curr Opin Chem Biol; 2013 Jun; 17(3):320-8. PubMed ID: 23683349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Global issues in drug development for Alzheimer's disease.
    Doody RS; Cole PE; Miller DS; Siemers E; Black R; Feldman H; Schindler R; Graham S; Heath T; Khachaturian AS; Evans R; Carrillo MC
    Alzheimers Dement; 2011 Mar; 7(2):197-207. PubMed ID: 21414556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Network-based analysis of complex diseases.
    Liu ZP; Wang Y; Zhang XS; Chen L
    IET Syst Biol; 2012 Feb; 6(1):22-33. PubMed ID: 22360268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.
    Roses AD
    Neuropsychopharmacology; 2009 Jan; 34(1):6-17. PubMed ID: 18923406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk in CNS drug discovery: focus on treatment of Alzheimer's disease.
    Pritchard JF
    BMC Neurosci; 2008 Dec; 9 Suppl 3(Suppl 3):S1. PubMed ID: 19090998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.